2025 Annual Meeting | C111 - Spinocerebellar and Spastic Ataxias: Diagnosis and Management

Date Monday 04/07/25

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Location San Diego Convention Center | 29CD

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Matthew R. Burns, MD, PhD

Topic(s) Movement Disorders

Learning Objectives Participants should be able to identify and describe the key clinical features and symptoms associated with various forms of spinocerebellar and spastic ataxias; learn to apply appropriate diagnostic techniques, including genetic testing and neuroimaging, to differentiate between types of ataxias; gain insights into current management strategies and therapeutic approaches for patients with spinocerebellar and spastic ataxias, including pharmacological and non-pharmacological interventions; understand the importance of a multidisciplinary approach in the management of ataxia patients, emphasizing a patient-centered care model; review recent advancements in research related to spinocerebellar and spastic ataxias, including experimental therapies and potential clinical trials; discuss effective communication strategies for counseling patients and families, including discussing prognosis and expectations in the context of progressive ataxias; and analyze case studies to highlight best practices in diagnosing and managing complex cases of ataxia.

This program is supported in part by an educational grant from PTC Therapeutics, Inc.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:40 PM PDT	Speaker	Diagnosis and Management of SCAs: Review and Update Matthew R. Burns, MD, PhD
01:40 PM - 02:20 PM PDT	Speaker	Friedreich's Ataxia (FA) S H. Subramony, MBBS, FAAN
02:20 PM - 03:00 PM PDT	Speaker	Genetic Testing for Ataxias Lee Kugelmann

Faculty Disclosures
Matthew R. Burns, MD, PhD	The institution of Dr. Burns has received research support from NIH. The institution of Dr. Burns has received research support from Mcknight Brain Institute.
S H. Subramony, MBBS, FAAN	Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dyne. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fallonmedica. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fulcrum. The institution of Dr. Subramony has received research support from Reata. The institution of Dr. Subramony has received research support from Retrotope. The institution of Dr. Subramony has received research support from Acceleron. The institution of Dr. Subramony has received research support from Biohaven. The institution of Dr. Subramony has received research support from Pharnext. The institution of Dr. Subramony has received research support from Fulcrum. The institution of Dr. Subramony has received research support from National Ataxia Foundation. The institution of Dr. Subramony has received research support from Friedreich Ataxia Research Alliance. The institution of Dr. Subramony has received research support from Muscular Dystrophy Association. The institution of Dr. Subramony has received research support from Univ of Rochester, MDA. The institution of Dr. Subramony has received research support from Virginia Commonwealth Univ (FDA, Wyck Foundation)). The institution of Dr. Subramony has received research support from Children's Hospital, Philadelphia (FDA). The institution of Dr. Subramony has received research support from Houston Methodist (NIH). The institution of Dr. Subramony has received research support from NIHR01 AR076060-01A1 . The institution of Dr. Subramony has received research support from NIH2R42HD089804-04 . The institution of Dr. Subramony has received research support from NIH R01 AR056973 . The institution of Dr. Subramony has received research support from FSHD Society. The institution of Dr. Subramony has received research support from AAVANTI BIO. The institution of Dr. Subramony has received research support from COHAV FL State Dept of Health. The institution of Dr. Subramony has received research support from Avidity. The institution of Dr. Subramony has received research support from PTC. The institution of Dr. Subramony has received research support from Biohaven. The institution of Dr. Subramony has received research support from Fulcrum. The institution of Dr. Subramony has received research support from Vertex. The institution of Dr. Subramony has received research support from Arthrex.
Lee Kugelmann	Lee Kugelmann has nothing to disclose.

��ɫ��

��ɫ��